Since an association between HCV genotypes and from Ͻ1% to Ͼ80%. The aim of the study was to determine whether differing HCV genotypes could account degrees of cytopathogenicity has previously been indicated, particularly in immunosuppressed patients, 8, 9 and considerfor the different severity of post-transplant liver disease (LD). Sera from patients with pre (n = 22) or post-BMT ing that their geographical distribution differs widely, 10 this raises the question of their role in determining the severity (n = 35) HCV infection were collected from Italy (Genova, Monza), Sweden (Huddinge) and Germany of liver disease after bone marrow transplant.
To study this hypothesis, we investigated the genotype (Ulm). Patients were grouped as follows: LF: 19/57; acute hepatitis (AH): 10/57 or chronic hepatitis (CH) : of HCV in infected patients undergoing allogeneic BMT. These patients were transplanted in four European Centres 22/57; no liver disease (LD): 6/57. HCV genotypes were identified by hybridisation of the 5ЈUTR amplified pro-(two in Italy, one in Germany and one in Sweden), where death due to liver failure ranged from less than 1% to more ducts with type-specific oligonucleotides probes according to Simmonds (Hepatology 1994; 19: 1321-1324).
than 80% in HCV-infected cases. Genotype HCV 1 was identified in 34 patients (60%), HCV 2 in 15 (26%), HCV 3 in three (5%), mixed infection in three (5%) and undefined in two (3.5%). In the Materials and methods LF group HCV 1 was identified in 10/19 and other genotypes in 9/19. Median timing of LF was earlier in
We collected sera from four BMT units that had previously published data on HCV-RNA-positive patients describing patients infected with HCV 1 compared to other genotypes (45 and 68 days, respectively), largely due to the various degrees of liver disease severity following bone marrow transplantation. Fifty-seven such cases, with HCV cause of LF; death from veno-occlusive disease (VOD) and hepatitis occurred at 30 and 68 days post-BMT, infection occurring before (n = 22) or after (n = 35) BMT, were identified. Thirty had been treated in Italy (15 at S respectively. Genotype 1 was also identified in cases with no LD. These data indicate that there was no evident Martino Hospital, Genova and 15 at S Gerardo Hospital, Monza), 19 at Huddinge University Hospital, Sweden and correlation between HCV genotype and type or severity of post-transplant liver disease.
eight at Ulm University Hospital, Germany. There were 34 males and 23 females and the mean age at transplant was Keywords: hepatitis C virus genotypes; BMT 17 years (range 2-47 years). Ten patients underwent BMT for severe aplastic anaemia, 10 for chronic myeloid leukaemia, 11 for acute myeloid leukaemia, 20 for acute lymLiver disorders following bone marrow transplantation phoblastic leukaemia, one for a myelodysplastic syndrome, (BMT) represent a major cause of morbidity and mortality.
four for thalassemia major and one for Gaucher disease. The prevalence of death due to liver failure is reported Details regarding the conditioning regimen and graft-verto be approximately 5-15% and is mainly attributed to sus-host disease (GVHD) prophylaxis have been published veno-occlusive disease (VOD). The determinants of such a elsewhere. [4] [5] [6] complication are still unknown. Surviving patients were followed up for a median of Hepatitis C virus infection is frequently found in these 3980 days (range 1365-5290), while time to death in fatal cases was bin time had been evaluated before the conditioning regi-men, at 2-3 day intervals during the first month after was not statistically significant. Among 27 children (age р15 years), 17 (63%) were infected with genotype HCV 1 transplant, weekly for the next 2 months and every 2 weeks for an additional 9 months. Thereafter, patients were evaluand 10 (37%) with other genotypes, showing no significant difference in prevalence compared with the adult patients ated at least every 3 months for 2 years and then at least once a year. Tests were carried out at closer intervals when (P = 1). Liver failure occurred in 19/57 patients: genotype HCV clinically indicated. Patients were grouped according to type of post-transplant liver disease, as follows: (1) Liver 1 was identified in 10/19 (53%) but this event was also observed in patients infected with other genotypes (9/19, failure (LF): 19/57 patients (33.3%) died of liver failure due to VOD (n = 7) and subacute hepatitis (n = 12) with or 47%) such as HCV 2 (6/19), HCV 3 (1/19) and in cases of mixed infection (1/19) or in cases where the genotype without liver graft-versus-host disease. A clinical diagnosis of subacute liver failure was made according to standard could not be defined (1/19) ( Table 2 ). Liver failure in the 10 patients infected with genotype 1 was due to VOD in classification 11 and VOD was diagnosed clinically according to Jones's criteria. 12 (2) Acute hepatitis (AH): 10/57 5/10 and to subacute hepatitis with or without liver GVHD in the remaining five. Among the patients infected with patients (17.5%) showed abnormal transaminase levels lasting less than 6 months after BMT. (3) Chronic hepatitis other genotypes, 2/9 died of VOD and 7/9 of subacute hepatitis with or without liver GVHD. Although there was (CH): 22/57 patients (38.5%) had abnormal transaminase levels lasting more than 6 consecutive months after transa trend indicating a predominance of VOD events in the HCV 1-infected group, the difference did not reach statistiplant. (4) No liver disease (no LD): 6/57 patients (10.5%) had normal transaminase levels for the whole observation cal significance (P = 0.2), possibly due to the small number of cases. The clinical characteristics of liver failure were period following BMT.
Details of methods for HCV-RNA detection by PCR similar in all groups. Death in the HCV 1 group occurred earlier than in the have been already described. 5 HCV genotypes, classified according to Simmonds et al, 13 were identified in serum others (median timing: 45 and 68 days post-transplant respectively), but this difference was entirely due to VOD by hybridisation of 5ЈUTR amplified products with typespecific oligonucleotides probes, according to Tisminetzky being the most common cause of liver failure. Indeed, median timing of death in patients with VOD was 30 days et al.
14 post-transplant, compared to 68 days in cases dying of subacute hepatitis. Figure 1 illustrates the course of liver failure after Results transplant in three patients infected with differing HCV genotypes. Overall results showed that genotype HCV 1 was found in 34 patients (60%), HCV 2 was identified in 15 cases (26%) Interestingly, genotype HCV 1 was not only identified in patients with acute or chronic hepatitis (21/32) but also and HCV 3 in three (5%). Mixed infections were demonstrated in three patients (5%), (HCV 1 + HCV 2 in two in 3/6 cases showing no liver complications after BMT (Table 2) . and HCV 2 + HCV 3 in one) while in the remaining two cases (3.5%) the genotype could not be defined. Table 1 illustrates the geographical distribution of HCV genotypes at the four BMT units. As expected, HCV 1 was the preDiscussion dominant genotype in all four BMT units, accounting for at least half of the HCV infections. However, HCV 2 was
The pathogenesis of hepatitis C is still largely unknown and it is unclear how the virus itself and the host immune also common, ranging from 12.5% in Ulm to 40% in Genova. A small proportion of cases were infected with response contribute to liver damage. This lack of information makes it impossible to predict how immunosup-HCV 3 (5-25%) or with mixed genotypes (HCV 1 + HCV 2 or HCV 2 + HCV 3).
pression might modify the course of the disease. The occurPatients infected with HCV 1 were slightly younger than those with other HCV genotypes or with mixed infection likely due to passive antibody transfer by blood transfusion or impaired immune response resulting from immunosuppression. 5 The possibility that different HCV genotypes may determine different risks for the development of fatal liver disease must also be considered. In our study, which contains the largest series of HCV-infected BMT patients reported to date, we were not able to identify a significant correlation between the genotype of infecting HCV and the severity of post-transplant liver disease. However, it must be taken into account that the number of patients studied is too small to draw definite conclusions. Although a proportion of cases developed liver failure after transplant, most patients showed asymptomatic chronic hepatitis, similar to that observed in non-immunocompromised patients and some, independently of the HCV infecting genotype, did not develop any liver complications. Hepatitis reactivation was a common event, mainly seen to occur after immune reconstitution, as suggested by the median timing of hepatic deterioration (68 days post-BMT) observed in the group with liver failure resulting from subacute hepatitis, in accordance with previous reports. 7, 15, 16 This finding suggests that careful monitoring of such patients is needed during the tapering of immunosuppressive drugs given for GVHD prophylaxis, to avoid an abrupt and possibly dangerous recovery of immunocompetence. In order to assess if, how and when immunosuppressive therapy could be discontinued without a major risk for life-threatening reactivation, our observation in this study cohort is ongoing.
Our data indicate that HCV genotypes per se do not seem to imply different clinical courses of post-transplant liver diseases, although further studies based on a larger number of BMT patients followed prospectively are needed to validate these conclusions. The pathogenesis of the severe hepatic decompensation observed in some of these patients is likely to be multifactorial, involving other hepatotoxic hepatitis following immune reconstitution after bone marrow transplantation, leading to death. 15, 16 McDonald et al 17 reported that pre-transplant non-A, non-B hepatitis correReferences lated with a high prevalence of VOD events, and the presence of abnormal transaminase levels before BMT with evi- 
